UCLA-Led Team Reports Results of Compassionate Use Treatment of 23 Severe/Critical COVID-19 Patients with CytoDyn’s Leronlimab; Possible Benefit of Leronlimab Suggested

Physicians from UCLA, together with collaborators, have reported tantalizingly positive anecdotal results from the compassionate use of the humanized monoclonal antibody lerorimab made by CytoDyn in the treatment of COVID-19 in 23 severely/critically ill patients. The results were reported online on October 20, 2020 in Clinical Infectious Diseases (https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1583/5932277?searchresult=1). The open-access article is titled “Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab.” The research team, led by Otto Yang, MD, in UCLA’s Department of Medicine, followed 23 hospitalized severe/critical COVID-19 patients who received 700 mg leronlimab subcutaneously, repeated after seven days in 17/23 patients still hospitalized. 18/23 also received other experimental treatments, including convalescent plasma, hydroxychloroquine, steroids, and/or tocilizumab. 5/23 received leronlimab after blinded placebo-controlled trials of remdesivir, sarilumab, selinexor, or tocilizumab. Outcomes and results were extracted from medical records. The mean age of the 23 patients was 69.5±14.9 years. 20/23 had significant co-morbidities. At baseline, 22/23 were receiving supplemental oxygen (3/23 high flow, 7/23 mechanical ventilation). Blood showed markedly elevated inflammatory markers (ferritin, D-dimer, C-reactive protein) and elevated neutrophil:lymphocyte ratio. By day 30 after initial dosing, 17/23 were recovered, 2/23 were still hospitalized, and 4/23 had died. Of the 7 intubated at baseline, 4/7 were fully recovered off oxygen, 2/7 were still hospitalized, and 1/7 had died. Based on this data, the researchers concluded that lerolimab appeared safe and well tolerated.
Login Or Register To Read Full Story